文献速递头颈与中枢神经肿瘤

卡瑞利珠单抗联合化疗一线治疗复发或转移性鼻咽癌的5年生存结局:CAPTAIN-1st随机临床试验二次分析

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

该研究为CAPTAIN-1st随机双盲3期试验的预设二次分析,纳入263例初治复发或转移性鼻咽癌患者,比较卡瑞利珠单抗联合吉西他滨和顺铂与安慰剂联合化疗的5年总生存。

要点

  • 卡瑞利珠单抗联合化疗较单纯化疗显著改善5年OS,绝对差异13.6%。
  • 联合组EBV DNA快速清除者OS显著更长(HR 0.32,95%CI 0.18-0.58)。
  • 这是首个支持PD-1联合化疗一线治疗复发/转移性鼻咽癌5年获益的证据。

核心结论

  • 在复发或转移性鼻咽癌一线治疗中,卡瑞利珠单抗联合化疗较单纯化疗产生统计学显著且临床有意义的5年OS获益。
  • 这是首个支持PD-1为基础的化学免疫治疗在该人群中5年获益的证据。

研究设计与样本

  • CAPTAIN-1st为随机、双盲、3期试验,在中国28家医院开展。
  • 2018年11月13日至2019年11月29日入组初治复发或转移性鼻咽癌患者,共263例随机(卡瑞利珠单抗组134例,安慰剂组129例)。
  • 患者1:1随机接受卡瑞利珠单抗或安慰剂联合吉西他滨和顺铂4-6周期,后续维持治疗至疾病进展、不可接受毒性或完成2年治疗。
  • 本次为预设的二次分析,数据截至2025年6月1日。

主要发现

  • 卡瑞利珠单抗组和安慰剂组中位生存随访分别为63.5个月(95%CI 61.2-64.6)和63.0个月(95%CI 60.8-64.6)。
  • 卡瑞利珠单抗组死亡85例(63.4%),安慰剂组死亡95例(73.6%)。

临床怎么用

  • 对于初治复发或转移性鼻咽癌患者,可考虑卡瑞利珠单抗联合吉西他滨和顺铂作为一线治疗以改善长期生存。
  • 治疗中监测EBV DNA清除情况可能有助于识别生存获益更显著的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 inhibitors plus chemotherapy is the current standard first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). However, the long-term survival benefits at the 5-year benchmark remain uncertain. OBJECTIVE: To determine whether adding camrelizumab to chemotherapy significantly improved 5-year overall survival (OS) as first-line treatment for RM-NPC, compared with chemotherapy alone. DESIGN, SETTING, AND PARTICIPANTS: The CAPTAIN-1st trial was a randomized, double-blind, phase 3 trial conducted at 28 hospitals in China. Between November 13, 2018, and November 29, 2019, patients with treatment-naive RM-NPC were enrolled. This secondary analysis of the CAPTAIN-1st trial was prespecified. Data analysis was conducted on June 1, 2025. INTERVENTIONS: Patients were randomized (1:1) to receive camrelizumab or placebo in combination with gemcitabine and cisplatin for 4 to 6 cycles, followed by maintenance therapy with camrelizumab or placebo until disease progression, unacceptable toxic effects, or completion of 2 years of treatment. MAIN OUTCOME: The primary end point, progression-free survival per independent review committee, has been reported previously. Herein, the secondary end point of OS is reported as prespecified in the protocol. RESULTS: Among 263 randomized patients (134 in randomized to camrelizumab, 129 to placebo), baseline characteristics were generally balanced between groups, except for age. The mean (SD) age was 49 (11.25) years, and 218 patients (82.9%) were male individuals, 45 (17.1%) were female individuals. With a median survival follow-up of 63.5 (95% CI, 61.2-64.6) months for the camrelizumab group and 63.0 (95% CI, 60.8-64.6) months for the placebo group, 85 (63.4%) and 95 (73.6%) deaths occurred, respectively. Median OS was 34.5 months (95% CI, 29.4-45.7) with camrelizumab vs 26.6 months (95% CI, 19.8-33.5) with placebo (hazard ratio [HR], 0.74; 95% CI, 0.55-0.99; 2-sided P = .047). After adjusting for age imbalance, the HR was 0.65 (95% CI, 0.48-0.89; P = .01). The 5-year OS rates were 37.8% vs 24.2%, reflecting an absolute difference of 13.6% (95% CI, 2.4%-24.8%; P = .02) in favor of camrelizumab. The OS benefits were generally consistent across subgroups. In the camrelizumab group, patients who achieved rapid clearance of Epstein-Barr virus (EBV) DNA had significantly longer OS compared with those without EBV DNA clearance (HR, 0.32; 95% CI, 0.18-0.58; P < .001). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, the addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of RM-NPC. These findings provided the first 5-year evidence supporting the benefit of PD-1-based chemoimmunotherapy in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03707509.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Huang Y, Sun D, Zhou H, et al. Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 41609753. doi:10.1001/jamaoncol.2025.6245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。